Phase 2 Metastatic Triple-Negative Breast Carcinoma trials recruiting now
All Metastatic Triple-Negative Breast Carcinoma trials, every phase
11
Phase 2 recruiting
Other phases for Metastatic Triple-Negative Breast Carcinoma
Phase 2 Metastatic Triple-Negative Breast Carcinoma trials
- A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer
- Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy
- DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs
- Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
- Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer
- Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
- Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
- Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast Cancer
- Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
- Treatment of Advanced or Metastatic Triple-negative Breast Cancer With Adoptive Therapy of PD1+ TILS
Common questions
What does Phase 2 mean?
Is this list complete?
No. For the full record, search ClinicalTrials.gov.